2016-2017年中国丙型肝炎哨点监测分析

丁国伟; 叶少东; 黑发欣; 连巧龄; 裴晓迪; 柏建芸; 周丹; 杨晴; 惠珊; 王伟; 屠爱霞; 庞琳

Abstract

丁国伟,叶少东,黑发欣,连巧龄,裴晓迪,柏建芸,周丹,杨晴,惠珊,王伟,屠爱霞,庞琳.2016-2017年中国丙型肝炎哨点监测分析[J].Chinese journal of Epidemiology,2019,40(1):41-45

2016-2017年中国丙型肝炎哨点监测分析

Sentinel surveillance for viral hepatitis C in China, 2016-2017

Received:April 03, 2018

DOI：10.3760/cma.j.issn.0254-6450.2019.01.009

KeyWord: 丙型肝炎病毒抗体阳性率哨点监测

English Key Word: Hepatitis C virus Antibody positive prevalence Sentinel surveillance

FundProject:

Author Name	Affiliation	E-mail
Ding Guowei	Division of HCV and STD Prevention and Treatment, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
Ye Shaodong	Division of HCV and STD Prevention and Treatment, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
Hei Faxin	Division of HCV and STD Prevention and Treatment, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
Lian Qiaoling	Department of High Risk Population Intervention, Institute of AIDS/STD Prevention and Treatment, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350001, China
Pei Xiaodi	Surveillance Department, Institute of STD/AIDS Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China
Bai Jianyun	Epidemiology Department, Division of AIDS/STD Control and Prevention, Tianjin Center for Disease Control and Prevention, Tianjin 300011, China
Zhou Dan	Institute of AIDS/STD Control and Prevention, Liaoning Provincial Center for Disease Control and Prevention, Shenyang 110005, China
Yang Qin	Institute of AIDS/STD Control and Prevention, Jiangxi Provincial Center for Disease Control and Prevention, Nanchang 330029, China
Hui Shan	Institute of AIDS/STD Control and Prevention, Heilongjiang Provincial Center for Disease Control and Prevention, Harbin 150030, China
Wang Wei	Institute of AIDS/STD Prevention and Treatment, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang 050021, China
Tu Aixia	Department of AIDS/STD Control and Prevention, Gansu Provincial Center for Disease Control and Prevention, Lanzhou 730030, China
Pang Lin	Division of HCV and STD Prevention and Treatment, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China	panglin@chinaaids.cn

Hits: 4549

Download times: 1552

Abstract:

目的监测中国丙型肝炎（丙肝）哨点5类人群HCV感染率，为评估丙肝的流行趋势和评价防控效果提供数据。方法全国31个省（自治区、直辖市）设立87个国家级丙肝哨点，对无偿献血者、单位体检者、医院侵入性诊疗患者、血液透析患者以及计划生育门诊就诊者5类哨点人群进行监测，了解HCV感染状况。2016、2017年4-6月以重复横断面调查方法，对5类哨点人群开展丙肝监测，同时采集血样进行HCV抗体检测。结果 2016年86个哨点（1个哨点未能开展调查）完成了监测，监测人数115 841人，HCV总阳性检出率为0.38%（442/115 841，95% CI：0.23%~0.53%）。2017年87个哨点完成了监测，监测人数120 486人，HCV总阳性检出率为0.37%（449/120 486，95% CI：0.23%~0.52%）。2016、2017年丙肝哨点监测人群中，血液透析患者的HCV抗体阳性率分别为4.46%（223/5 005，95% CI：2.18%~6.73%）和4.39%（216/4 919，95% CI：2.29%~6.50%），医院侵入性诊疗患者的HCV抗体阳性率分别为0.85%（44/5 200，95% CI：0.27%~1.42%）和0.70%（36/5 150，95% CI：0.15%~1.24%），无偿献血者、单位体检者和计划生育门诊就诊者3类人群的HCV抗体阳性率均≤ 0.25%，5类监测人群HCV抗体阳性率比较，差异有统计学意义（2016年，F=23.091，P<0.001；2017年，F=20.181，P<0.001）。结论 5类监测人群HCV抗体阳性率存在明显差异，血液透析患者HCV抗体阳性率最高，其次为医院侵入性诊疗患者HCV抗体阳性率，其他3类监测人群的HCV抗体阳性率维持在较低水平。

English Abstract:

Objective To understand the prevalence of hepatitis C virus (HCV) infection in 5 populations in China during 2016-2017 and provide evidence for the estimation of prevalence trend of hepatitis C and evaluation on the prevention and control effect. Methods A total of 87 national sentinel surveillance sites for hepatitis C were set up in 31 provinces (autonomous regions and municipalities) of China to obtain the information about HCV infection prevalence in 5 populations, including volunteer blood donors, people receiving physical examination, patients receiving invasive diagnosis and treatment, patients receiving hemodialysis, and clients visiting family planning outpatient clinics. From April to June, 2016 and 2017, cross-sectional surveys were repeatedly conducted in the 5 populations and blood samples were collected from them for HCV antibody detection. Results In 2016, 86 sentinel sites completed the surveillance (one sentinel site was not investigated), and 115 841 persons were surveyed. The overall HCV positive rate was 0.38% (442/115 841, 95% CI:0.23%-0.53%). In 2017, all the 87 sentinel sites completed the surveillance, and 120 486 persons were surveyed. The overall HCV positive rate was 0.37% (449/120 486, 95% CI:0.23%-0.52%). In 2016 and 2017, the anti-HCV positive rates were 4.46% (223/5 005, 95% CI:2.18%-6.73%) and 4.39% (216/4 919, 95% CI:2.29%-6.50%) respectively in hemodialysis patients, 0.85% (44/5 200, 95% CI:0.27%-1.42%) and 0.70% (36/5 150, 95% CI:0.15%-1.24%) respectively in patients receiving invasive diagnosis and treatment and remained to be ≤ 0.25% in volunteer blood donors, people receiving physical examination and clients visiting family planning outpatient clinics. Results for the comparison of the anti-HCV positive rates in the 5 populations indicated that the differences were significant (F=23.091, P<0.001 in 2016 and F=20.181, P<0.001 in 2017). Conclusions Data from the sentinel surveillance of HCV infection on prevalence in China showed that the anti-HCV positive rates varied in the 5 populations during 2016-2017. The anti-HCV positive rate appeared the highest in the hemodialysis patients, followed by that in the patients receiving invasive diagnosis and treatment, and the prevalence of HCV infection in other 3 populations were at low levels.

View Fulltext Html FullText View/Add Comment Download reader